Allurion Technologies Stock Surges on FDA Progress and Debt Restructuring Moves

Shares of Allurion Technologies Inc. (NYSE:ALUR) popped more than 10% in early trading Tuesday after the company unveiled positive developments on two critical fronts. The weight-loss medical device maker gained FDA traction and announced a strategic debt exchange deal, signaling a potential turning point for its financial health and regulatory path.

The company shared that it has cleared significant hurdles in the FDA Pre-Market Approval (PMA) process for its flagship Allurion Smart Capsule. Allurion successfully passed the FDA's pre-approval and Bioresearch Monitoring inspections without any citations or findings. Additionally, the firm completed the Day-100 Meeting with regulators, with no further requests for human clinical data, suggesting confidence in their submission.

Dr. Shantanu Gaur, CEO and Founder, emphasized these achievements as landmark moments, highlighting the firm's advancement toward the final FDA review stages. Given the typical complexity and delays often associated with device approvals, pushing through with zero findings in inspections is a noteworthy signal of regulatory compliance and readiness.

Financially, the company declared a plan to swap out all outstanding debt by issuing new Series B Convertible Preferred Stock. This preferred stock will carry an 8.25% dividend and can convert at an initial price of $3.37 per share, though the deal requires shareholder approval and closing conditions. This move aims to wipe out the company's debt load and clean up the balance sheet ahead of any potential U.S. commercial rollout.

Alongside the debt exchange news, Allurion raised $5 million through a private placement, involving new and existing investors plus a strategic obesity-treatment partner. This infusion came with the sale of almost 3 million shares and warrants at $1.67 apiece, reinforcing the company's cash reserves as it eyes FDA approval and market entry.

Allurion's PMA pathway was already in motion when the company submitted its final application module in June 2025. The subsequent Acceptance and Filing Reviews wrapped up by July, progressing to the Substantive Review phase. These FDA procedural milestones outline a clearer timeframe and reduce some uncertainty hanging over the company's regulatory prospects.

With competitors jostling for position in the obesity treatment space, Allurion's Smart Capsule-a non-surgical, swallowable weight-loss device-needs solid regulatory and financial footing. This recent combination of clean FDA checkpoints and capital restructuring could set the stage for a pivotal year ahead.

Of course, while the FDA process advances and the balance sheet receives a makeover, ALUR shares remain sensitive to how these developments translate into sales and market penetration, areas that will crystallize in the quarters to come.